SyntheX

Executive Summary

SyntheX is a San Diego-based biotechnology company leveraging its proprietary ToR FLEx platform to discover small molecule drugs against historically challenging protein targets. Founded in 2020, the company employs a target-centric, cell-based functional selection approach that enables the identification of novel chemical matter for targets previously considered undruggable. Initially focused on building an internal oncology pipeline, SyntheX also seeks strategic collaborations to expand the application of its platform across other therapeutic areas. Despite being in a preclinical stage, the company’s innovative technology has the potential to address significant unmet medical needs, particularly in oncology where many critical targets remain beyond the reach of conventional drug discovery methods. SyntheX operates in the highly competitive small molecule drug discovery space, but its distinctive selection-based platform differentiates it from traditional screening and rational design approaches. The company is privately held with no disclosed funding or valuation, suggesting it may be operating in stealth or early venture stages. Key near-term milestones include advancing lead programs toward candidate nomination, securing partnership deals with larger pharmaceutical companies, and closing a series A financing round. Success in these areas would validate the platform’s utility and provide the capital needed to progress toward the clinic.

Upcoming Catalysts (preview)

• Q4 2026Lead Optimization and Candidate Nomination for First Oncology Program40% success
• Q2 2026Announcement of Strategic Pharma Partnership30% success
• Q3 2026Series A Financing Round50% success